Related Experiment Video
Updated: Jun 20, 2026
Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury
Published on: March 7, 2022
A bibliometric study related to the treatment of myocardial ischemia-reperfusion Injury
Jie Feng1, Leilei Han1, Yunman Liu1
1Department of Cardiology, The Second Affiliated Hospital, Jiangxi Medical college, Nanchang University, Nanchang, 330006, China.
Background:
Myocardial ischemia-reperfusion injury (MIRI) is defined as the restoration of blood flow to the myocardium after a brief interruption of blood supply, causing more severe damage to the ischemic myocardium. However, currently, reperfusion therapy is the preferred therapy for ischemic cardiomyopathy, which undoubtedly causes MIRI, and thus it has become a challenging issue affecting the prognosis of coronary artery disease.
Methods:
A search was conducted in the Web of Science Core Collection database for papers relevant to MIRI therapy published between 1 January 2000 and 1 October 2023. Bibliometric analyses were performed using VOSviewer and CiteSpace to elucidate the progress and hotspots.
Results:
3304 papers from 64 countries, 2134 research institutions and 13,228 authors were enrolled in the study. Of these, China contributed the most papers and had the biggest impact, while the United States had the most extensive partnership. The Fourth Military Medical University was the primary research institution. The most valuable authors include Chattipakorn, Nipon, Chattipakorn, Siriporn c, Yang, Jian and Yang, Yang.
Conclusion:
Over the past 20 years, research on MIRI therapies has made significant strides. Further studies are necessary to explore the interactions between various therapeutic options. Future investigations will emphasize nanocarriers, cardiac regeneration, and stem cell therapies. Our study identifies MIRI research hotspots from a bibliometric perspective, forecasts future trends, and offers fresh insights into MIRI therapy research.
Insights
Myocardial ischemia-reperfusion injury (MIRI) research has advanced significantly. Future MIRI therapies will focus on nanocarriers, cardiac regeneration, and stem cells, offering new insights for coronary artery disease treatment.
Area of Science:
- Cardiology
- Biomedical Science
Background:
- Myocardial ischemia-reperfusion injury (MIRI) exacerbates damage after blood flow restoration.
- MIRI is a significant challenge in treating ischemic cardiomyopathy and coronary artery disease.
Purpose of the Study:
- To analyze global research trends and hotspots in MIRI therapy.
- To identify key contributors and emerging research areas in MIRI treatment.
Main Methods:
- Bibliometric analysis of 3304 MIRI therapy papers (2000-2023).
- Utilized VOSviewer and CiteSpace for data analysis.
- Included papers from 64 countries and 2134 institutions.
Main Results:
- China leads in MIRI research publications and impact; the US excels in international collaboration.
- The Fourth Military Medical University is a leading research institution.
- Identified key authors and their contributions to the field.
Conclusions:
- MIRI therapy research has progressed substantially over two decades.
- Future research will likely focus on nanocarriers, cardiac regeneration, and stem cell therapies.
- This bibliometric study provides insights into MIRI research hotspots and future directions.
Related Concept Videos
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...